Alnylam Pharmaceuticals Inc annual operating income for fiscal TTM was $752 million, an increase of 49.8% from $502 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Operating Income (annual) | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (EBIT) | $752M | $502M | ($177M) | ($282M) | ($785M) | ($709M) | ($828M) | ($939M) | ($815M) | ($500M) | ($425M) | ($296M) | ($405M) | ($93M) | ($129M) | ($55M) | ($44M) | ($48M) | ($28M) | ($93M) | ($40M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Operating Income (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Operating Income (EBIT) | $269M | $132M | $368M | ($16M) | $18M | ($105M) | ($77M) | $49M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More ALNY metrics: Revenue · Gross Profit · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All ALNY financial statements → Interactive ALNY charts →
About TickerBase · Data methodology & sources